Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
2.
Indian J Ophthalmol ; 68(3): 536-538, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32057028

RESUMO

A 31-year-old male presented with decreased vision in the right eye associated with an active plaque-like serpiginoid choroiditis. The lesion showed a unique feature of dual margins of hyperautofluorescence of the lesion on fundus autofluoresence (FAF) imaging. Systemic investigations suggested a tubercular etiology. He was started on antitubercular treatment and a conventional dose of oral corticosteroids (1mg/kg body weight). However, the lesions showed paradoxical worsening and required increased immunosuppression in the form of local steroids and oral immunomodulators. The presence of dual margins of hyperautofluorescence could suggest increased inflammatory activity leading to paradoxical worsening on treatment requiring increased immunosuppression.


Assuntos
Antituberculosos/uso terapêutico , Corioide/diagnóstico por imagem , Angiofluoresceinografia/métodos , Coroidite Multifocal/diagnóstico , Tomografia de Coerência Óptica/métodos , Tuberculose Ocular/diagnóstico , Acuidade Visual , Adulto , Corioide/microbiologia , Progressão da Doença , Seguimentos , Fundo de Olho , Humanos , Masculino , Coroidite Multifocal/tratamento farmacológico , Mycobacterium tuberculosis/isolamento & purificação , Tuberculose Ocular/tratamento farmacológico
4.
Indian J Ophthalmol ; 67(1): 105-108, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30574903

RESUMO

PURPOSE: To identify optical coherence tomography-angiography (OCT-A) findings to predict treatment response during anti-vascular endothelial growth factor (VEGF) therapy in eyes with para foveal telangiectasia (PFT) group II. METHODS: In this retrospective series, Twelve eyes of seven patients diagnosed with PFT group II without evidence of sub-retinal neovascular membrane (SRNVM) clinically or on spectral domain-OCT (SD-OCT) were included. All patients underwent OCT-A on the Topcon DRI OCT Triton® with 4.5 mm macula scans. The patients with abnormal vascular nets were further classified into type A and B nets and administered intravitreal anti-VEGF therapy. Visual acuity and size of type A and B nets were evaluated pre- and post-injection. Paired t- test and intraclass correlation were used to analyse data. RESULTS: Patients with type A net showed significant improvement in visual acuity (logMAR 0.38, P = 0.0047). The size of type A net showed statistically significant decrease (P = 0.0008) on 6 month follow up. Type B net did not show statistically significant difference in visual acuity or size following anti-VEGF therapy. CONCLUSION: OCT-A plays an important role in early detection of possible neovascular nets (type A), in the absence of obvious SRNVM. Treatment decisions based on OCT-A may be helpful to achieve better visual outcome.


Assuntos
Bevacizumab/administração & dosagem , Angiofluoresceinografia/métodos , Fóvea Central/irrigação sanguínea , Ranibizumab/administração & dosagem , Telangiectasia Retiniana/tratamento farmacológico , Vasos Retinianos/patologia , Tomografia de Coerência Óptica/métodos , Adulto , Idoso , Inibidores da Angiogênese/administração & dosagem , Feminino , Seguimentos , Fóvea Central/diagnóstico por imagem , Fundo de Olho , Humanos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Telangiectasia Retiniana/diagnóstico , Vasos Retinianos/efeitos dos fármacos , Estudos Retrospectivos , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Acuidade Visual
5.
Indian J Ophthalmol ; 66(2): 252-255, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29380769

RESUMO

PURPOSE: The aim of this study is to establish the safety of storage and reuse of bevacizumab vials for 1 week with multiple vial punctures. METHODS: This was an experimental microbiological study conducted at tertiary care hospital. The study samples included bevacizumab vials that had been used for injecting patients by the pooling method. Vials were stored and sampled in a manner that replicated their proposed clinical use. Contamination of vials was evaluated on the basis of microbial culture and validated by positive and negative controls. The probability of obtaining such results purely by chance was calculated. RESULTS: A total of 210 samples from 30 vials were evaluated along with 210 positive and 210 negative controls. No growth was seen in any of the bevacizumab samples. The probability of obtaining 210 consecutive sterile samples just by chance is <5.547 × 10-6 (0.000005547). CONCLUSION: The vials showed no contamination on storage for 7 days in an ordinary refrigerator. Thus, we conclude that the rate of contamination of bevacizumab vials on storage for 7 days in a refrigerator is likely to be insignificant. The results need to be validated by other studies replicating this protocol.


Assuntos
Bevacizumab/farmacologia , Contaminação de Medicamentos/estatística & dados numéricos , Embalagem de Medicamentos , Armazenamento de Medicamentos/métodos , Endoftalmite/etiologia , Infecções Oculares Bacterianas/etiologia , Estabilidade de Medicamentos , Endoftalmite/microbiologia , Infecções Oculares Bacterianas/microbiologia , Humanos , Injeções Intravítreas/efeitos adversos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...